Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Bintrafusp alfa in MSI-H cancers following progression on immunotherapy

Arvind Dasari • 22 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer General Bintrafusp alfa

Arvind Dasari, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an ongoing Phase II study evaluating bintrafusp alfa in patients with metastatic microsatellite-high (MSI-H) cancers following progression on immunotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Arvind Dasari

1:30
How will fruquintinib fit in the colorectal cancer treatment landscape?
Arvind Dasari • 27 Jan 2023
2:27
Fruquintinib in treating metastatic colorectal cancer
Arvind Dasari • 27 Jan 2023
3:16
The utility of ctDNA in colorectal cancer management
Arvind Dasari • 27 Jan 2023
2:20
Updates from the CIRCULATE-US trial
Arvind Dasari • 27 Jan 2023

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals